Incremental Cost-Effectiveness Ratios (ICERs) and Revised Generic Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes Study

Sultan Alolayan, Tewodros Eguale, Alissa R. Segal, Joanne Doucette, Brian E. Rittenhouse, College of Pharmacy, Taibah University, Saudi Arabia, Massachusetts College of Pharmacy and Health Sciences, School of Pharmacy, Department of Pharmaceutical and Administrative Sciences, Brigham and Women, s Hospital, Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women, s Hospital, Diabetes Section, Massachusetts College of Pharmacy and Health Sciences, School of Pharmacy, Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Department of Library and Learning Resources

American Journal of Lifestyle Medicine

Published online on January 21, 2025

Abstract

American Journal of Lifestyle Medicine, Ahead of Print.
Introduction:Based on previously published US Diabetes Prevention Program (DPP) cost-effectiveness analyses (CEAs), “metformin” (branded or generic) continues to be promoted as “cost-effective.” We reviewed a 10-year CEA to assess this. Treatment ...